Mass Tort brief
Bellwether Settlements and High Opt-In Thresholds Reshape Injury Dockets
Federal judges are ratcheting up pressure on mass tort defendants to establish structured exit funds or face imminent jury trials.
Mass Tort
Johnson & Johnson's $5.5B talc settlement faces a decisive test — requiring 95% claimant participation to resolve nearly 70,000 federal cancer lawsuits.
BackgroundDecades of litigation allege Johnson & Johnson's cosmetic baby powder contained trace asbestos that caused ovarian cancer and mesothelioma in consumers. Johnson & Johnson maintains that its talc products are safe and asbestos-free, pursuing class settlement mechanisms to permanently end its litigation liability.
- The settlement framework was crafted after the court ordered plaintiffs to show cause why claims should not be dismissed following expert witness withdrawals.
- Claimants who opt out of the $5.5B agreement must satisfy heightened individual causation proof standards on the active trial docket, raising litigation barriers.
- Plaintiff leadership committees are conducting nationwide informational forums to secure required voting thresholds before the court's registration cutoff.
Mass Tort
Judges ordered mandatory settlement talks in the Camp Lejeune litigation — imposing an October 30 deadline as the first bench trial approaches.
BackgroundThe Camp Lejeune Justice Act allows military veterans and families to seek financial compensation for illnesses caused by toxic base tap water between 1953 and 1987. While administrative payouts under the Navy's Elective Option have surpassed $879M, hundreds of thousands of claims remain stalled in litigation.
- Judge Terrence W. Boyle scheduled opening arguments in the Mousser and Fancher kidney cancer bellwether trials for late October and early November.
- The Department of Justice confirmed issuing over $1.1B in administrative Elective Option offers through late September, seeking to trim pending federal caseloads.
- Litigation leaders were extended through October 2027 to oversee coordinated negotiations if the October 30 global framework deadline fails to yield an accord.
Mass Tort
Uber resolved its third test case on the courtroom steps — choosing private settlements over public jury awards while 5,000 passenger claims wait for a global deal.
BackgroundFederal lawsuits consolidated before U.S. District Judge Charles Breyer claim Uber used lax driver background checks and failed to address recurring passenger safety complaints. Previous test trials produced conflicting jury awards of $8.5M and $5,000, leaving both sides without a clear damages benchmark.
- Uber stipulated during jury selection that it would not dispute the assault occurred, pivoting its defense entirely to corporate liability shields to avoid inflammatory witness testimony.
- The plaintiff alleged Uber's screening overlooked active criminal warrants, clearing a driver who was subsequently convicted of sexual assault and sentenced to 11 years in prison.
- Judge Charles Breyer and plaintiff steering committees have increased mediation sessions, signaling that repeated bellwether settlements must transition toward a comprehensive fund.
Mass Tort
Pfizer's Depo-Provera MDL established a formal compensation structure — giving 6,400 claimants until late November to join an administrative exit or face strict trial hurdles.
BackgroundThe multidistrict litigation alleges that prolonged exposure to medroxyprogesterone acetate significantly increases the risk of developing intracranial meningioma tumors. Pfizer continues to dispute general scientific causation while negotiating an administrative compensation model to cap exposure.
- Case Management Orders 15 and 16 appointed Matt Garretson as Allocation Master and CPA Randall Sansom to run the Supplemental Compensation Fund.
- Claimants participating in the administrative resolution program must complete formal registration by November 30, 2026, or risk exclusion from initial payout tiers.
- Plaintiffs who decline the compensation structure must submit heightened individualized medical causation proof to proceed on the active trial docket.
Mass Tort
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
